Kevin Tozer, MD
Ophthalmology · Scottsdale, AZNPI 1912269689
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $21,378 of the $32,301 with a category attached, or 66.2%. Glaukos Corporation accounts for 81.7% of it on its own, with 29 other manufacturers making up the rest. 2025 is the largest year on record at $11,891, 7.2 times the $1,654 reported in 2019. Among ophthalmology clinicians in AZ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 283 payments — averaging $114.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Glaukos Corporation$26K
- Dompe US, Inc.$847
- AbbVie$808
- Bausch & Lomb Americas Inc.$796
- Novartis$466
- Alcon$388
- plus $3K from 24 others
What the payments were for
- Consulting fees$21,37866%
- Speaking & faculty fees$320%
- Travel & lodging$2,0946%
- Food & beverage$8,79827%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Glaukos Corporation | 67 | $26,405 |
| Dompe US, Inc. | 17 | $847 |
| AbbVie(2 entities) | 37 | $808 |
| Bausch & Lomb Americas Inc. | 37 | $796 |
| Novartis | 20 | $466 |
| Alcon | 14 | $388 |
| Carl Zeiss Meditec USA, Inc. | 4 | $349 |
| Johnson & Johnson Surgical Vision, Inc. | 4 | $264 |
| Tarsus Pharmaceuticals, Inc. | 6 | $239 |
| Rxsight Inc | 8 | $235 |
| Sun Pharmaceutical Industries Inc. | 10 | $210 |
| Aerie Pharmaceuticals, Inc. | 9 | $172 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 8 | $162 |
| Harrow Eye, LLC | 7 | $153 |
| Oyster Point Pharma, Inc. | 4 | $97 |
| Kala Pharmaceuticals, Inc. | 5 | $94 |
| Genentech USA, Inc. | 1 | $81 |
| Amgen | 4 | $72 |
| Heidelberg Engineering, Inc. | 1 | $68 |
| Biotissue Holdings Inc. | 2 | $64 |
| Rayner Intraocular Lenses Limited | 3 | $61 |
| Mallinckrodt Hospital Products Inc. | 2 | $60 |
| Eyevance Pharmaceuticals LLC | 3 | $53 |
| Shire North American Group Inc | 3 | $49 |
| Thea Pharma Inc. | 1 | $22 |
| NEW World Medical,inc. | 2 | $21 |
| Eyepoint US, Inc. | 1 | $20 |
| Lensar, Inc. | 1 | $18 |
| Ocular Therapeutix, Inc. | 1 | $17 |
| Akorn Operating Company LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- KXL System$9,497
- CE-marked KXLA system$3,450
- iStent inject W$3,264
- Travoprost Intraocular Implant - iDose$2,383
- ILINK$2,000
- Epioxa$1,250
- Photrexa$517
- iStent inject Trabecular Micro-Bypass Stent System$346
- Oxervate$265
- iDoseTR$204
- IACCESS$159
- ENVISTA ENVY IOL$150
- iStent$124
- Tecnis Simplicity$119
- Whitestar Signature Pro$119
- DURYSTA$119
- BEOVU$106
How this compares
$32,301 in reported general payments places this provider in the 95th percentile of 310 ophthalmology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 148 | $166,120 |
| XiidraLifitegrast | 39 | $56,047 |
| LumiganBimatoprost | 65 | $43,803 |
| Cyclosporine | 40 | $27,648 |
| XdemvyLotilaner | 11 | $19,985 |
| VyzultaLatanoprostene Bunod | 39 | $19,366 |
| Prednisolone Acetate | 320 | $14,293 |
| RocklatanNetarsudil Mesylat/Latanoprost | 26 | $10,571 |
| MieboPerfluorohexyloctane/Pf | 13 | $9,912 |
| Brinzolamide | 30 | $6,033 |
| CombiganBrimonidine Tartrate/Timolol | 11 | $4,996 |
| Latanoprost | 568 | $4,806 |
| TafluprostTafluprost/Pf | 21 | $4,336 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 17 | $4,276 |
| Dorzolamide-TimololDorzolamide/Timolol/Pf | 13 | $3,990 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan, Alphagan P | $808 | $218,726236 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta, Miebo | $796 | $85,32591 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $239 | $19,98511 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan | $172 | $10,57126 claims |
| AlconSimbrinza | $388 | $4,27617 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $162 | $1,47216 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 310 ophthalmology providers in Arizona.
Other ophthalmology in Scottsdale
- Mark BarakatScottsdale$794K
- Jay SchwartzScottsdale$30K
- Dharmendra PatelScottsdale$20K
- Paul PetelinScottsdale$20K
- Stephen HwangScottsdale$14K
- James GoldmanScottsdale$11K
- Linda TsaiScottsdale$7K
- Steve ChecrounScottsdale$6K
- Sarah MakiScottsdale$6K
- Craig SuiterScottsdale$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.